Frontier mental health research: psychedelics & drug studies

Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.

15 papers

Ayahuasca for Sadness or low mood

Based on 15 papers

Research on ayahuasca for sadness and low mood shows promise but is still early. Lab and animal studies suggest its active ingredient, DMT, can change brain connections. Small human trials and patient reports find mood improvements for some people, especially in hard-to-treat depression. However, most clinical studies are small or preliminary. Safety, who the results apply to, and exactly how the brew helps are not settled. Scientists say more large, careful trials with diverse participants and good medical oversight are needed.

Key findings

  • Ayahuasca is a traditional plant brew. One plant provides DMT and the other has chemicals that stop the body from breaking DMT, so the DMT works when you drink it (not just when injected or smoked). 15082 15059
  • In lab and animal studies, DMT and related compounds can make neurons grow new branches and form more connections, which could help change mood. But some animal studies found different effects depending on dose or sex, so results are not uniform. 15050 15082
  • Small clinical studies and early human trials report reductions in depression symptoms after ayahuasca or DMT treatments, with the strongest and most consistent promise for treatment‑resistant major depression so far. 15082 15060 15063
  • Overall evidence in humans is still limited. Many trials are small or early‑stage, so researchers say larger and better‑controlled studies are needed before firm conclusions can be drawn. 15082 15063 15085
  • Patients often describe helpful psychological processes such as personal insight, a changed sense of self, and feeling more connected to others. These kinds of experiences — plus preparation and therapy before and after the session — are strongly linked to better outcomes. 15092 15063 15091
  • Safety matters. Reviews and experts stress the need for medical oversight, careful set and setting, and follow‑up care. The growing psychedelic industry also raises ethical and legal questions that affect how treatments are delivered. 15091 15085 15082
  • A large review of many psychoplastogen studies found no clear rise in blood levels of BDNF (a protein sometimes linked to brain change) after these drugs. That suggests blood BDNF may not be a reliable marker of how these drugs affect the human brain. 15129
  • Most past psychedelic therapy studies included mostly White participants. Because ayahuasca comes from Indigenous traditions and people of color were underrepresented in research, study results may not apply to all cultural or ethnic groups. 15095 15058 15082

Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature

Timothy I. Michaels, Jennifer Purdon, Alexis Collins, Monnica T. Williams
BMC Psychiatry Summary & key facts 2018 247 citations

The authors reviewed psychedelic-assisted psychotherapy studies published from 1993 to 2017 to see how many people of color took part. They found 18 studies with about 280 people. About 82% of participants were non-Hispanic White, while only small percentages were African American, Latino, Asian, indigenous, or mixed race. Because so…

Natural Compound Pharmacology Studies Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies Ayahuasca LSD

Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms

Antonio Inserra, Danilo De Gregorio, Gabriella Gobbi
Pharmacological Reviews Summary & key facts 2020 215 citations

This review looked at many studies about classic psychedelics (like psilocybin and LSD), MDMA, ketamine, and plant medicines (like ayahuasca). The authors explain how these drugs can change the brain’s wiring, calm inflammatory processes, and shift key brain chemicals. Those actions may help explain why small clinical trials and animal…

Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies Tryptophan and brain disorders Ayahuasca Ketamine

Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies

Joost J. Breeksema, Alistair Niemeijer, Erwin Krediet, Eric Vermetten, Robert A. Schoevers
CNS Drugs Summary & key facts 2020 207 citations

Researchers collected and read 15 studies where patients described their own experiences with psychedelic treatments for mental disorders. These studies looked at about 180 patient accounts across different drugs and different illnesses. Even though the drugs and treatment settings were very different, many patients described similar helpful processes, such as…

Chemical synthesis and alkaloids Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies Ayahuasca Ibogaine

Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders

Henry Lowe, Ngeh J. Toyang, Blair Steele, Justin Grant, Amza Ali, Lorenzo Gordon, et al.
Molecules Summary & key facts 2022 52 citations

This paper is a review of research about psychedelic drugs and whether they could help with mood and anxiety problems. It explains that these drugs were used for thousands of years in some cultures, then were banned in the 1960s which slowed scientific study. The authors describe a new wave…

Chemical synthesis and alkaloids Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies Ayahuasca LSD

A century of research on psychedelics: A scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, entheogens and dissociative drugs

Marco Solmi, Chaomei Chen, Charles Daure, Anne Buot, Michael Ljuslin, Vincent Verroust, et al.

Researchers looked at published papers about psychedelic drugs from the last century, using citation maps and other tools to see how the field changed up to March 2022. They found that research was small and mostly about safety for many decades, then grew a lot after the 1990s into a…

Forensic Toxicology and Drug Analysis Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies Ayahuasca Ketamine

Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry

Jacob S. Aday, Brian S. Barnett, Dan Grossman, Kevin S. Murnane, Charles D. Nichols, Peter S. Hendricks
Psychedelic Medicine Summary & key facts 2023 49 citations

This article is a broad review of the new psychedelic industry. The authors look at how psychedelic drugs and clinics moved from decades-old research into a fast-growing business with hundreds of companies and big investment. They describe what companies are trying to sell, point out major scientific, legal, and ethical…

Chemical synthesis and alkaloids Diverse academic research themes Psychedelics and Drug Studies Ayahuasca Ibogaine

The Emerging Field of Psychedelic Psychotherapy

Gregory Barber, Scott T. Aaronson
Current Psychiatry Reports Summary & key facts 2022 48 citations

This review looks at recent research where drugs like MDMA and psilocybin are given inside carefully run therapy programs. People get hours of preparation, one or more drug sessions, and several follow-up therapy sessions to help make sense of the experience. Trials so far show big improvements for some people…

Chemical synthesis and alkaloids Diverse academic research themes Psychedelics and Drug Studies Ayahuasca Ibogaine

Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism

Jennifer Mitchell, B. Anderson
Neuropsychopharmacology Summary & key facts 2023 44 citations

This review describes a rapid rise in medical research on psychedelic drugs over the past five years. Several later-stage clinical trials have been published, and many different drugs — including psilocybin, MDMA, ketamine, LSD, ayahuasca, and ibogaine — are being tested for conditions such as depression, post‑traumatic stress, addiction, obsessive‑compulsive…

Chemical synthesis and alkaloids Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies Ayahuasca Ibogaine

Psychedelics in the treatment of unipolar and bipolar depression

Oliver G. Bosch, Simon Halm, Erich Seifritz

This paper reviews past and recent research on classic psychedelics and some newer psychedelic-like drugs as treatments for unipolar and bipolar depression. Classic psychedelics named in the paper are LSD, psilocybin, mescaline, and ayahuasca. Early carefully controlled studies of psilocybin show encouraging results for unipolar depression, and ketamine (in the…

Chemical synthesis and alkaloids Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies Ayahuasca Ketamine

Serotonergic Psychedelics in Neural Plasticity

Kacper Łukasiewicz, Jacob J. Baker, Yi Zuo, Ju Lu

This review explains that classical serotonergic psychedelics — drugs like psilocybin, DMT (in ayahuasca), LSD, and ibogaine — can change brain cells and connections in lab and animal studies. These drugs have been shown to help neurons grow new branches and form more synapses, which are the contact points where…

Chemical synthesis and alkaloids Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies Ayahuasca Ibogaine

Is the Requirement for First-Person Experience of Psychedelic Drugs a Justified Component of a Psychedelic Therapist’s Training?

Nathan Emmerich, Bryce Humphries

This paper looks at whether trainee psychedelic therapists should be required to take psychedelic drugs so they can understand patients' experiences. The authors review the idea that first-person psychedelic trips give special knowledge, and they argue this benefit is not clearly unique or proven. They conclude that forcing trainees to…

Chemical synthesis and alkaloids Diverse academic research themes Psychedelics and Drug Studies Ayahuasca Ketamine

Effects of Psychedelics in Older Adults: A Prospective Cohort Study

Hannes Kettner, Leor Roseman, Adam Gazzaley, Robin Carhart‐Harris, Lorenzo Pasquini

Researchers followed 62 older adults (age 60 and up) and 62 younger adults who planned to take part in guided psychedelic group sessions. People in both age groups reported better well-being in the weeks after the sessions, but older adults experienced weaker immediate drug effects during the sessions. For older…

Biochemical Analysis and Sensing Techniques Chemical synthesis and alkaloids Psychedelics and Drug Studies Ayahuasca LSD
Summaries and links are for general information and education only. They are not a substitute for reading the original publication or for professional medical, legal, or other advice. Always refer to the linked source for the full study.